Drug intelligence / Profile preview

DGT-SM-Cancer3

Development stage: Preclinical
Lead developer: dGenThera
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

DGT-SM-Cancer3 is an undisclosed small-molecule targeted radiotherapeutic currently in the discovery stage of development by dGenThera. The candidate is designed to target specific cellular transporters that are overexpressed in certain types of cancer, facilitating the delivery of a radioactive isotope directly to the tumor site. This approach aims to maximize therapeutic efficacy while minimizing off-target toxicity to healthy tissues. As of early 2024, the specific molecular target and the primary cancer indication (referred to as 'Cancer 3') have not been publicly disclosed by the developer.

Other names: dGenThera Cancer 3 small molecule radiotherapeutic

Targets

SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on DGT-SM-Cancer3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DGT-SM-Cancer3.

Explore the full profile